Joaquin Duato, J&J CEO (Jacquelyn Martin/AP Images)
April 16, 2024 02:40 PM EDTUpdated 03:01 PM
Pharma

J&J’s mul­ti­ple myelo­ma ther­a­pies dri­ve on­col­o­gy busi­ness de­spite slow Carvyk­ti sales

Katherine Lewin

News Reporter

John­son & John­son de­fend­ed slow­er-than-ex­pect­ed sales of Carvyk­ti in the first quar­ter, with ex­ecs say­ing they ex­pect sales of the cell ther­a­py to ac­cel­er­ate in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times